Content area

|
|

Erytropoietin som mulig behandling ved hjernesygdom

Forfatter(e)

Kamilla Woznica Miskowiak1, 2

1) Institut for Psykologi, Københavns Universitet, 2) Psykiatrisk Center København, Region Hovedstadens Psykiatri, Rigshospitalet

Ugeskr Læger 2020;182:V04200287

Reference: 
UgeskrLæger 2020;182:V04200287
Blad nummer: 
Erythropoietin as possible treatment of brain diseases

Kamilla Woznica Miskowiak

Ugeskr Læger 2020;182:V0420287

Erythropoietin (EPO) is a hypoxia-inducible hormone best known for its role in erythropoiesis. However, EPO also has anti-inflammatory and tissue-protective characteristics in multiple organs as summarised in this review. In the brain, EPO is upregulated by hypoxia, regulates ventilation and plays a key role in neuroprotection and neuroplasticity. Systemically administered EPO crosses the blood-brain-barrier, enhances neuroplasticity and improves cognitive functions in several disorders of the brain. Given this evidence, a trial is being planned to investigate whether EPO can improve the physiologic and neurologic outcome of COVID-19.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Torben Mahneke | 22/10
1 Kommentar
af Flemming Amter | 19/10
1 Kommentar
af Henrik Dibbern | 18/10
1 Kommentar
af Jens Langhoff-Roos | 17/10
3 kommentarer
af Tomas Christensen Kjær | 16/10
1 Kommentar
af Lars Lindberg Andersen | 15/10
1 Kommentar
af Johan Tommy Robert Wallentin | 14/10
1 Kommentar